Search

Your search keyword '"Lazaro, Estibaliz"' showing total 248 results
Start Over Author "Lazaro, Estibaliz" Search Limiters Peer Reviewed
248 results on '"Lazaro, Estibaliz"'

1. Inflammasome-targeted therapy might prevent adverse perinatal outcomes of recurrent chronic intervillositis of unknown etiology

Author

Mattuizzi, Aurélien, Sauvestre, Fanny, Fargeix, Tiphaine, White, Eoghann, Leibler, Claire, Cargou, Marine, Dugot-Senant, Nathalie, Douchet, Isabelle, Duluc, Dorothée, Bordes, Cécile, Truchetet, Marie-Élise, Richez, Christophe, Forcade, Édouard, Duffau, Pierre, Viallard, Jean-François, Sentilhes, Loïc, Blanco, Patrick, and Lazaro, Estibaliz

Published
2024
Full Text
View/download PDF

3. VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation

Author

Kosmider, Olivier, Possémé, Céline, Templé, Marie, Corneau, Aurélien, Carbone, Francesco, Duroyon, Eugénie, Breillat, Paul, Chirayath, Twinu-Wilson, Oules, Bénédicte, Sohier, Pierre, Luka, Marine, Gobeaux, Camille, Lazaro, Estibaliz, Outh, Roderau, Le Guenno, Guillaume, Lifermann, François, Berleur, Marie, Le Mene, Melchior, Friedrich, Chloé, Lenormand, Cédric, Weitten, Thierry, Guillotin, Vivien, Burroni, Barbara, Boussier, Jeremy, Willems, Lise, Aractingi, Selim, Dionet, Léa, Tharaux, Pierre-Louis, Vergier, Béatrice, Raynaud, Pierre, Ea, Hang-Korng, Ménager, Mickael, Duffy, Darragh, and Terrier, Benjamin

Published
2024
Full Text
View/download PDF

4. Rôle des médecins hospitalo-universitaires de médecine interne dans la formation aux métiers de la santé et au sein des institutions en France : enquête du Collège National des Enseignants de Médecine Interne (CEMI)

Author

Rauzy, Odile, Bouillet, Laurence, Chevalier, Kevin, Cohen-Aubart, Fleur, Delacroix, Isabelle, Hanslik, Thomas, Kaplanski, Gilles, Lazaro, Estibaliz, Le Moigne, Emmanuelle, Pottier, Pierre, Riviere, Etienne, and Mouthon, Luc

Published
2024
Full Text
View/download PDF

5. Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency

Author

Le Voyer, Tom, Parent, Audrey V., Liu, Xian, Cederholm, Axel, Gervais, Adrian, Rosain, Jérémie, Nguyen, Tina, Perez Lorenzo, Malena, Rackaityte, Elze, Rinchai, Darawan, Zhang, Peng, Bizien, Lucy, Hancioglu, Gonca, Ghillani-Dalbin, Pascale, Charuel, Jean-Luc, Philippot, Quentin, Gueye, Mame Sokhna, Maglorius Renkilaraj, Majistor Raj Luxman, Ogishi, Masato, Soudée, Camille, Migaud, Mélanie, Rozenberg, Flore, Momenilandi, Mana, Riller, Quentin, Imberti, Luisa, Delmonte, Ottavia M., Müller, Gabriele, Keller, Baerbel, Orrego, Julio, Franco Gallego, William Alexander, Rubin, Tamar, Emiroglu, Melike, Parvaneh, Nima, Eriksson, Daniel, Aranda-Guillen, Maribel, Berrios, David I., Vong, Linda, Katelaris, Constance H., Mustillo, Peter, Raedler, Johannes, Bohlen, Jonathan, Bengi Celik, Jale, Astudillo, Camila, Winter, Sarah, McLean, Catriona, Guffroy, Aurélien, DeRisi, Joseph L., Yu, David, Miller, Corey, Feng, Yi, Guichard, Audrey, Béziat, Vivien, Bustamante, Jacinta, Pan-Hammarström, Qiang, Zhang, Yu, Rosen, Lindsey B., Holland, Steve M., Bosticardo, Marita, Kenney, Heather, Castagnoli, Riccardo, Slade, Charlotte A., Boztuğ, Kaan, Mahlaoui, Nizar, Latour, Sylvain, Abraham, Roshini S., Lougaris, Vassilios, Hauck, Fabian, Sediva, Anna, Atschekzei, Faranaz, Sogkas, Georgios, Poli, M. Cecilia, Slatter, Mary A., Palterer, Boaz, Keller, Michael D., Pinzon-Charry, Alberto, Sullivan, Anna, Droney, Luke, Suan, Daniel, Wong, Melanie, Kane, Alisa, Hu, Hannah, Ma, Cindy, Grombiříková, Hana, Ciznar, Peter, Dalal, Ilan, Aladjidi, Nathalie, Hie, Miguel, Lazaro, Estibaliz, Franco, Jose, Keles, Sevgi, Malphettes, Marion, Pasquet, Marlene, Maccari, Maria Elena, Meinhardt, Andrea, Ikinciogullari, Aydan, Shahrooei, Mohammad, Celmeli, Fatih, Frosk, Patrick, Goodnow, Christopher C., Gray, Paul E., Belot, Alexandre, Kuehn, Hye Sun, Rosenzweig, Sergio D., Miyara, Makoto, Licciardi, Francesco, Servettaz, Amélie, Barlogis, Vincent, Le Guenno, Guillaume, Herrmann, Vera-Maria, Kuijpers, Taco, Ducoux, Grégoire, Sarrot-Reynauld, Françoise, Schuetz, Catharina, Cunningham-Rundles, Charlotte, Rieux-Laucat, Frédéric, Tangye, Stuart G., Sobacchi, Cristina, Doffinger, Rainer, Warnatz, Klaus, Grimbacher, Bodo, Fieschi, Claire, Berteloot, Laureline, Bryant, Vanessa L., Trouillet Assant, Sophie, Su, Helen, Neven, Benedicte, Abel, Laurent, Zhang, Qian, Boisson, Bertrand, Cobat, Aurélie, Jouanguy, Emmanuelle, Kampe, Olle, Bastard, Paul, Roifman, Chaim M., Landegren, Nils, Notarangelo, Luigi D., Anderson, Mark S., Casanova, Jean-Laurent, and Puel, Anne

Published
2023
Full Text
View/download PDF

6. Severe adult hemophagocytic lymphohistiocytosis (HLHa) correlates with HLH-related gene variants

Author

Bloch, Coralie, Jais, Jean Philippe, Liffermann, Francois, Morel, Pierre, Cheminant, Morgane, Suarez, Felipe, Hermine, Olivier, Bonnet, Fabrice, Godemer, Pascal, Gandhi, Damaj, Fain, Olivier, Lambotte, Olivier, Launay, David, Terriou, Louis, Larroche, Claire, Lazaro, Estibaliz, Viallard, Jean-Francois, Lortholary, Olivier, Michel, Marc, Michot, Jean-Marie, Pene, Frederic, Perlat, Antoinette, Urbanski, Geoffrey, Gil, Marine, Boubaya, Marouane, Lepelletier, Yves, Bader-Meunier, Brigitte, Mahlaoui, Nizar, Garcelon, Nicolas, Alcais, Alexandre, Fischer, Alain, and de Saint Basile, Geneviève

Published
2024
Full Text
View/download PDF

7. Case Studies and Literature Review of Francisella tularensis--Related Prosthetic Joint Infection

Author

Ponderand, Lea, Guimard, Thomas, Lazaro, Estibaliz, Dupuy, Henry, Peuchant, Olivia, Roch, Nathalie, Deroche, Philippe, Ferry, Tristan, Maurin, Max, Hennebique, Aurelie, Boisset, Sandrine, Pelloux, Isabelle, and Caspar, Yvan

Subjects
Francisella tularensis -- Case studies, Artificial joints -- Complications and side effects -- Case studies, Zoonoses -- Case studies -- Causes of, Gram-negative bacterial infections -- Case studies -- Causes of, Health
Abstract

Francisella tularensis is a fastidious, gram-negative coccobacillus that can cause tularemia, a zoonotic disease. Two subspecies are responsible for human cases: F. tularensis subspecies tularensis (type A strains) and F. [...]

Published
2023
Full Text
View/download PDF

11. Clinical features and long-term outcomes of patients with systemic polyarteritis nodosa diagnosed since 2005: Data from 196 patients

Author

Ackermann, Felix, Aumaitre, Olivier, Bussone, Guillaume, Catalan, Pilartxo, Chasset, François, Crabol, Yoann, de Moreuil, Claire, Hot, Arnaud, Humbert, Marc, Chiche, Noémie Jourde, Le Gallou, Thomas, Leroux, Dominique, Mesbah, Rafik, Mouthon, Luc, Pagnoux, Christian, Revuz, Sabine, Rieu, Laurent, Schmidt, Jean, Vandergheynst, Frederic, Rohmer, Julien, Nguyen, Yann, Trefond, Ludovic, Agard, Christian, Allain, Jean Sebastien, Berezne, Alice, Charles, Pierre, Cohen, Pascal, Gondran, Guillaume, Groh, Matthieu, Huscenot, Tessa, Lacout, Carole, Lazaro, Estibaliz, London, Jonathan, Maurier, François, Mekinian, Arsène, Nubourgh, Isabelle, Perard, Laurent, Puéchal, Xavier, Pugnet, Gregory, Puyade, Mathieu, Queyrel, Viviane, Roux, Arthur, Rouzaud, Diane, Durel, Cecile-Audrey, Guillevin, Loïc, and Terrier, Benjamin

Published
2023
Full Text
View/download PDF

13. Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study

Author

AUDEMARD-VERGER, Alexandra, AZZI, Emmanuel, BANNEVILLE, Béatrice, BAUDET, Antoine, BEAUDOUIN BAZIRE, Constance, BELIZNA, Cristina, Belot, Alexandre, BENHAMOU, Ygal, Berezné, Alice, BERNARD-GUERVILLY, Fanny, BERTHIER, Sabine, BEZANAHARY, Holy, BIALE, Lisa, BIGOT, Adrien, BLANCHARD-DELAUNAY, Claire, CALAS, Anne, CAMPAGNE, Julien, CATHEBRAS, Pascal, CAZALETS, Claire, CHAIGNE, Benjamin, CHANDESRIS, Olivia, CHATELAIS, Jérémy, CHATELUS, Emmanuel, COHEN, Fleur, Combe, Bernard, COMPARON, Céline, COQUERELLE, Pascal, DAMIAN, Louise, DAUGAS, Eric, DE MENTHON, Mathilde, DE MOREUIL, Claire, DELATTRE, Estelle, DELLAL, Azeddine, Deneux-Tharaux, Catherine, DENIS, Amélie, DEPROUW, Camille, DERNIS, Emmanuelle, DEROUX, Alban, DESOUCHES, Sandra, Dieudé, Philippe, DIREZ, Guillaume, Dougados, Maxime, DRIESSEN, Marine, DU THANH, Aurélie, DUNOGEANT, Laetitia, DURANT, Cécile, DUREL, Cécile-Audrey, DURIEU, Isabelle, EBOUE, Florence, Elefant, Elisabeth, FAIN, Olivier, FAUTREL, Bruno, FLIPO, René-Marc, FRAZIER, Aline, FROISSART, Antoine, GEORGIN-LAVIALLE, Sophie, GERVAIS, Elisabeth, GODEAU, Bertrand, Goffinet, François, GOMPEL, Anne, GOSSEC, Laure, GOUPILLE, Philippe, GRANGE, Claire, GUILLAUD-DANIS, Constance, HACHULLA, Eric, HOEFSLOOT, Sabine, HUMMEL, Aurélie, JEGO, Patrick, JOBARD, Stéphanie, JOSSELIN-MAHR, Laurence, LAMBERT, Marc, LANGLOIS, Vincent, LARIVIERE, Delphine, LARROCHE, Claire, LATOURTE, Augustin, LAVIGNE, Christian, LE GALLOU, Thomas, LEROUX, Gaëlle, LETAROUILLY, Jean Guillaume, LIOTÉ, Frédéric, Loeuillet, Laurence, London, Jonathan, Loustau, Valentine, LOZAC'H, Pierre, MAHEU, Emmanuel, MAILLARD, Hélène, MAROTTE, Hubert, MASSEAU, Agathe, MEKINIAN, Arsène, Melboucy Belkhir, Sara, Miceli-Richard, Corinne, MICHAUD, Martin, MICHEL, Marc, MORANNE, Olivier, MORATI-HAFSAOUI, Chafika, MOULIS, Guillaume, MOUTHON, Luc, NICOLAS, Barbara, Nizard, Jacky, ORA, Jérémy, OUTH, Rodérau, PASQUIER, Elisabeth, PENNAFORTE, Jean-Loup, PERLAT, Antoinette, PETIT-BAUER, Hélène, PILLEBOUT, Evangeline, PIOT, Jean-Maxime, PORTIER, Agnès, Pourrat, Olivier, PUECHAL, Xavier, PUGNET, Gregory, REDONDIN, Manon, REGENT, Alexis, RORIZ, Mélanie, SAILLER, Laurent, SAVEY, Léa, SCHERLINGER, Marc, SCHLEINITZ, Nicolas, Sellam, Jérémie, Sentilhes, Loïc, SERVAIS, Aude, SMETS, Perrine, SORDET, Christelle, SOUBRIER, Martin, STANKOVIC-STOJANOVIC, Katia, URBANSKI, Geoffrey, VEIT, Véronique, WEBER, Emmanuelle, YELNIK, Cécile, de Frémont, Grégoire Martin, Costedoat-Chalumeau, Nathalie, Lazaro, Estibaliz, Belkhir, Rakiba, Guettrot-Imbert, Gaëlle, Morel, Nathalie, Nocturne, Gaétane, Molto, Anna, Goulenok, Tiphaine, Diot, Elisabeth, Perard, Laurent, Ferreira-Maldent, Nicole, Le Besnerais, Maelle, Limal, Nicolas, Martis, Nihal, Abisror, Noémie, Debouverie, Odile, Richez, Christophe, Sobanski, Vincent, Maurier, François, Sauvetre, Gaëtan, Levesque, Hervé, Timsit, Marie-Agnès, Tieulié, Nathalie, Orquevaux, Pauline, Bienvenu, Boris, Mahevas, Matthieu, Papo, Thomas, Lartigau-Roussin, Céline, Chauvet, Elodie, Berthoux, Emilie, Sarrot-Reynauld, Françoise, Raffray, Loïc, Couderc, Marion, Silva, Nicolas Martin, Jourde-Chiche, Noémie, Belhomme, Nicolas, Thomas, Thierry, Poindron, Vincent, Queyrel-Moranne, Viviane, Delforge, Juliette, Le Ray, Camille, Pannier, Emmanuelle, Mariette, Xavier, Le Guern, Véronique, and Seror, Raphaèle

Published
2023
Full Text
View/download PDF

14. Pleuropulmonary Manifestations of Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome

Author

Haroche, Julien, Amoura, Zahir, Pha, Micheline, Hie, Miguel, Meghit, Kilifa, Rondeau-Lutz, Murielle, Weber, Jean-Christophe, Borie, Raphael, Debray, Marie Pierre, Guedon, Alexis F., Mekinian, Arsene, Terriou, Louis, Lacombe, Valentin, Lazaro, Estibaliz, Meyer, Aurore, Mathian, Alexis, Ardois, Samuel, Vial, Guillaume, Moulinet, Thomas, Terrier, Benjamin, Jamilloux, Yvan, Heiblig, Mael, Bouaziz, Jean-David, Zakine, Eve, Outh, Roderau, Groslerons, Sylvie, Bigot, Adrien, Flamarion, Edouard, Kostine, Marie, Henneton, Pierrick, Humbert, Sebastien, Constantin, Arnaud, Samson, Maxime, Bertrand, Nadine Magy, Biscay, Pascal, Dieval, Celine, Lobbes, Herve, Jeannel, Juliette, Servettaz, Amelie, Adelaide, Leo, Graveleau, Julie, de Sainte-Marie, Benjamin, Galland, Joris, Guillotin, Vivien, Duroyon, Eugénie, Templé, Marie, Bourguiba, Rim, Georgin Lavialle, Sophie, Kosmider, Olivier, and Audemard-Verger, Alexandra

Published
2023
Full Text
View/download PDF

15. Precipitating factors of catastrophic antiphospholipid syndrome: the role of anticoagulant treatment in a series of 112 patients

Author

Stammler, Romain, Nguyen, Yann, Yelnik, Cécile, Le Guern, Véronique, Lambert, Marc, Paule, Romain, Hachulla, Eric, Mouthon, Luc, Dupré, Anastasia, Ackermann, Félix, Dufrost, Virginie, Wahl, Denis, Godeau, Bertrand, Leroux, Gaëlle, Benhamou, Ygal, Lazaro, Estibaliz, Daugas, Eric, Bezanahary, Holy, Mekinian, Arsène, Piette, Jean-Charles, Morel, Nathalie, and Costedoat-Chalumeau, Nathalie

Published
2023
Full Text
View/download PDF

17. Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, observational study

Author

Azzi, Emmanuel, Banneville, Béatrice, Baudet, Antoine, Beaudouin-Bazire, Constance, Belizna, Cristina, Belkhir, Rakiba, Berezne, Alice, Berthoux, Emilie, Berthier, Sabine, Biale, Lisa, Bienvenu, Boris, Blanchard-Delaunay, Claire, Cathebras, Pascal, Cazalets, Claire, Chaigne, Benjamin, Chandesris, Olivia, Chatelais, Jérémy, Chatelus, Emmanuel, Coquerelle, Pascal, Couderc, Marion, Delforge, Juliette, Denis, Amélie, Desouches, Sandra, Dieudé, Philippe, Direz, Guillaume, Driessen, Marine, Du Thanh, Aurélie, Dunogeant, Laetitia, Durant, Cécile, Durieu, Isabelle, Fabre, Marc, Fain, Olivier, Flipo, René-Marc, Frazier, Aline, Froissart, Antoine, Georgin-Lavialle, Sophie, Gervais, Elisabeth, Gompel, Anne, Gossec, Laure, Goupille, Phillipe, Grange, Claire, Guillaud-Danis, Constance, Hummel, Aurélie, Jallouli, Moez, Jego, Patrick, Jobard, Stéphane, Josselin-Mahr, Laurence, Jourde-Chiche, Noémie, Korganow, Anne-Sophie, Lambert, Marc, Lariviere, Delphine, Larroche, Claire, Lartigau-Roussin, Céline, Latourte, Augustin, Le Gallou, Thomas, Leroux, Gaëlle, Levesque, Hervé, Lioté, Frédéric, London, Jonathan, Loustau, Valentine, Maheu, Emmanuel, Mahevas, Matthieu, Maillard, Hélène, Mariette, Xavier, Marotte, Hubert, Martin-Silva, Nicolas, Martis, Nihal, Masseau, Agathe, Mekinian, Arsène, Melboucy-Belkhir, Sara, Michaud, Martin, Michel, Marc, Morati-Hafsaoui, Chafika, Nizard, Jacky, Ora, Jérémy, Pennaforte, Jean-Loup, Perlat, Antoinette, Petit Bauer, Hélène, Pillebout, Evangeline, Piot, Jean-Maxime, Portier, Agnès, Pugnet, Gregory, Redondin, Manon, Regent, Alexis, Richez, Christophe, Roriz, Mélanie, Sailler, Laurent, Sauvêtre, Gaëtan, Savey, Léa, Sobanski, Vincent, Sordet, Christelle, Soubrier, Martin, Stankovic Stojanovic, Katia, Thomas, Thierry, Timsit, Marie-Agnès, Tsatsaris, Vassilis, Murarasu, Anne, Guettrot-Imbert, Gaëlle, Le Guern, Véronique, Yelnik, Cécile, Queyrel, Viviane, Schleinitz, Nicolas, Ferreira-Maldent, Nicole, Diot, Elisabeth, Urbanski, Geoffrey, Pannier, Emmanuelle, Lazaro, Estibaliz, Souchaud-Debouverie, Odile, Orquevaux, Pauline, Belhomme, Nicolas, Morel, Nathalie, Chauvet, Elodie, Maurier, François, Le Besnerais, Maëlle, Abisror, Noemie, Goulenok, Tiphaine, Sarrot-Reynauld, Françoise, Deroux, Alban, Pasquier, Elisabeth, de Moreuil, Claire, Bezanahary, Holy, Pérard, Laurent, Limal, Nicolas, Langlois, Vincent, Calas, Anne, Godeau, Bertrand, Lavigne, Christian, Hachulla, Eric, Cohen, Fleur, Benhamou, Ygal, Raffray, Loïc, de Menthon, Mathilde, Tieulié, Nathalie, Poindron, Vincent, Mouthon, Luc, Larosa, Maddalena, Eléfant, Elisabeth, Sentilhes, Loic, Molto, Anna, Deneux-Tharaux, Catherine, and Costedoat-Chalumeau, Nathalie

Published
2022
Full Text
View/download PDF

18. Correlation of nailfold capillaroscopy findings with history of digital ulcer on same finger: Results of SCLEROCAP study

Author

Boulon, Carine, Velardo, Fanny, Blaise, Sophie, Mangin, Marion, Chevoir, Joelle Decamps-Le, Senet, Patricia, Lazareth, Isabelle, Baudot, Nathalie, Tribout, Laurent, Imbert, Bernard, Lapebie, François-Xavier, Dari, Loubna, Lacroix, Philippe, Truchetet, Marie-Elise, Seneschal, Julien, Solanilla, Anne, Lazaro, Estibaliz, Quéré, Isabelle, Pistorius, Marc-Antoine, Asselineau, Julien, Lhomme, Edouard, Carpentier, Patrick, and Constans, Joël

Published
2022
Full Text
View/download PDF

19. No Effect of Low-Dose Glucocorticoid Maintenance Therapy on Damage in SLE Patients in Prolonged Remission: A Propensity Score Analysis of the Longitudinal Lupus-Cruces-Bordeaux Inception Cohort.

Author

Ruiz-Irastorza, Guillermo, Paredes-Ruiz, Diana, Dueña-Bartolome, Luis, Hernandez-Negrin, Halbert, Moreno-Torres, Victor, Richez, Christophe, and Lazaro, Estibaliz

Subjects
SYSTEMIC lupus erythematosus, POISSON regression, CLINICAL medicine, HYDROXYCHLOROQUINE, PREDNISONE
Abstract

Background/Objectives: Prolonged remission on low-dose glucocorticoids (GC) is a main goal in patients with systemic lupus erythematosus (SLE). The aim of this study is to assess whether GC ≤ 5 mg/d increases the risk of damage accrual in patients with SLE in prolonged remission. Methods: Observational study of routine clinical care data of the inception Lupus Cruces-Bordeaux cohort. Only patients in DORIS remission during five consecutive yearly visits were included. The endpoint was damage accrual during the 5-year follow-up, either global or specific damage: GC-induced, cardiovascular (CV), lupus and other. Patients no longer on GC therapy by year 5 (GC5-Off) were compared with those who continued GC therapy (GC5-On). Comparisons were made by Cox and Poisson regressions, which were adjusted with propensity score (PE) in order to control for confounding by indication. Results: 132 patients were included, 56 in the GC5-On and 76 in the GC5-Off groups. All patients were on GC ≤ 5 mg/d for the whole follow-up, the mean prednisone dose in the GC5-On group being 2.96 mg/d during the whole study period and 2.6 mg/d during the 5th year. Fourteen patients (10.6%) accrued damage. More patients in the GC5-On group accrued global damage, 16% vs. 7% in the GC5-Off group, p = 0.08, mainly at CV domains (7% vs. 1%, respectively, p = 0.16). In the PS-adjusted Cox and Poisson regressions, the GC5-On group was not significantly associated with global (p = 0.39) or CV damage accrual (p = 0.62), nor with the absolute (p = 0.40) or CV-restricted final SDI scores (p = 0.63). The C-index of the propensity score model was 0.79. Conclusions: Maintaining doses of prednisone < 5 mg/d in lupus patients in prolonged remission is not associated with an increased risk of damage accrual. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX.

Author

Hadjadj, Jerome, Yann Nguyen, Mouloudj, Dalila, Bourguiba, Rim, Heiblig, Mael, Aloui, Hassina, McAvoy, Chloe, Lacombe, Valentin, Ardois, Samuel, Campochiaro, Corrado, Maria, Alexandre, Coustal, Cyrille, Comont, Thibault, Lazaro, Estibaliz, Lifermann, Francois, Guenno, Guillaume Le, Lobbes, Hervé, Grobost, Vincent, Outh, Roderau, and Campagne, Julien

Published
2024
Full Text
View/download PDF

21. Mechanisms of systemic low-grade inflammation in HIV patients on long-term suppressive antiretroviral therapy: the inflammasome hypothesis

Author

Guerville, Florent, Vialemaringe, Marine, Cognet, Celine, Duffau, Pierre, Lazaro, Estibaliz, Cazanave, Charles, Bonnet, Fabrice, Leleux, Olivier, Rossignol, Rodrigue, Pinson, Benoît, Tumiotto, Camille, Gabriel, Frederic, Appay, Victor, Déchanet-Merville, Julie, Wittkop, Linda, Faustin, Benjamin, and Pellegrin, Isabelle

Published
2023
Full Text
View/download PDF

25. Practical management of patients on anti-IL6R therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI)

Author

Morel, Jacques, Tournadre, Anne, Sellam, Jérémie, Bouhnik, Yoram, Cornec, Divi, Devauchelle-Pensec, Valérie, Dieudé, Philippe, Goupille, Philippe, Kluger, Nicolas, Lazaro, Estibaliz, Le Goff, Benoit, de Lédinghen, Victor, Lequerré, Thierry, Nocturne, Gaëtane, Seror, Raphaèle, Truchetet, Marie-Elise, Verhoeven, Frank, Pham, Thao, and Richez, Christophe

Published
2021
Full Text
View/download PDF

26. Practical management of patients on anti-TNF therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI)

Author

Sellam, Jérémie, Morel, Jacques, Tournadre, Anne, Bouhnik, Yoram, Cornec, Divi, Devauchelle-Pensec, Valérie, Dieudé, Philippe, Goupille, Philippe, Jullien, Denis, Kluger, Nicolas, Lazaro, Estibaliz, Le Goff, Benoit, de Lédinghen, Victor, Lequerré, Thierry, Nocturne, Gaëtane, Seror, Raphaèle, Truchetet, Marie-Elise, Verhoeven, Frank, Pham, Thao, and Richez, Christophe

Published
2021
Full Text
View/download PDF

27. Practical management of patients on anti-IL17 therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI)

Author

Tournadre, Anne, Sellam, Jérémie, Morel, Jacques, Jullien, Denis, Bouhnik, Yoram, Cornec, Divi, Devauchelle-Pensec, Valérie, Goupille, Philippe, Kluger, Nicolas, Lazaro, Estibaliz, Goff, Benoit Le, Lédinghen, Victor de, Lequerré, Thierry, Nocturne, Gaëtane, Seror, Raphaèle, Truchetet, Marie-Elise, Verhoeven, Frank, Richez, Christophe, and Pham, Thao

Published
2021
Full Text
View/download PDF

28. Methylprednisolone Pulses and Prolonged Remission in Systemic Lupus Erythematosus: A Propensity Score Analysis of the Longitudinal Lupus‐Cruces‐Bordeaux Inception Cohort.

Author

Ruiz‐Irastorza, Guillermo, Paredes‐Ruiz, Diana, Herrero‐Galvan, Maria, Moreno‐Torres, Victor, Hernandez‐Negrin, Halbert, Ruiz‐Arruza, Ioana, Leonard, Cedric, Richez, Christophe, and Lazaro, Estibaliz

Subjects
SYSTEMIC lupus erythematosus, ODDS ratio, LOGISTIC regression analysis, CLINICAL medicine, CONFIDENCE intervals, LUPUS nephritis, DISEASE remission
Abstract

Objective: The objective of this study was to analyze the effect of methylprednisolone pulses (MP), given during the first year after the diagnosis of systemic lupus erythematosus (SLE), in achieving prolonged remission according to the degree of lupus activity at presentation. Methods: We conducted an observational study of routine clinical care data from the Lupus‐Cruces‐Bordeaux cohort. The end point was prolonged remission (ie, during five consecutive yearly visits). The effect of MP on remission during the first year was analyzed in the whole cohort and according to the baseline Systemic Lupus Erythematosus Disease Activity Index 2000 score: <6, 6 to 12, and >12, reflecting mild, moderate, and severe activity, respectively. For adjustment, logistic regression with propensity score (PS) and other therapeutic covariates was performed. Results: Two hundred thirty‐three patients were included. Prolonged remission was achieved by 132 patients (57%). MP were associated with prolonged remission (PS‐adjusted odds ratio [OR] 2.50, 95% confidence interval [CI] 1.04–623, P = 0.042). A strong clinical effect was seen among patients with moderate (adjusted OR 5.28, 95% CI 1.27–21.97, P = 0.022) and moderate‐severe SLE activity (adjusted OR 4.07, 95% CI 1.11–14.82, P = 0.033). The administration of MP resulted in reduced average dosages of prednisone during the first year among patient with moderate (mean 6.6 vs 10.2 mg/day, P = 0.017) and severe activity (mean 14 vs 28 mg/day, P = 0.015). The odds of prolonged remission were increased by longer‐term use of hydroxychloroquine (HCQ) and decreased by higher initial doses of prednisone. Conclusion: This study supports the use of MP to induce prolonged remission in patients with SLE, particularly in those with moderate and severe activity. The extended use of HCQ also contributes to achieve prolonged remission. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis.

Author

Eldani, Céline, Kostine, Marie, Faure, Maxime, Lazaro, Estibaliz, Rigothier, Claire, Hiriart, Jean Baptiste, Teulières, Bérénice, Poullenot, Florian, Haissaguerre, Magalie, Zysman, Maeva, Veillon, Rémi, Vergnenegre, Charlotte, Issa, Nahema, Domblides, Charlotte, Mary-Prey, Sorilla, Beylot-Barry, Marie, Pham-Ledard, Anne, Dutriaux, Caroline, Sole, Guilhem, and Duval, Fanny

Subjects
DRUG side effects, IMMUNE checkpoint inhibitors, RETROSPECTIVE studies, CARDIOVASCULAR system, CANCER patients
Abstract

Immune checkpoint inhibitors (ICIs) present clinicians with the challenge of managing immune-related adverse events (irAEs), which can range from mild to severe due to immune system activation. While guidelines recommend discontinuing ICIs for grade 3 partial and all grade 4 irAEs, there is growing interest in rechallenging patients based on oncological outcomes, particularly for cardiovascular and neurological irAEs where data remains scarce. We retrospectively evaluated the safety of ICI rechallenge following grade 3-4 irAEs, specifically focusing on cardiovascular and neurological events, in patients discussed at our multidisciplinary immunotoxicity assessment board between 2019 and 2021. Fifteen patients were included, with a median time to severe irAE onset of 49 days. Among them, five patients experienced neurological adverse events (NAEs): aseptic meningitis (3), inflammatory polyradiculoneuropathy (1), and ophthalmoplegia (1), while one patient presented with myocarditis. Of the 15 patients retreated with ICIs after initial severe irAEs, 11 (73%) remained free of subsequent irAEs, two (13%) experienced recurrence of the initial irAE, and two (13%) developed new irAEs distinct from the initial event. The median time to event recurrence was 69 days, occurring no earlier than the initial severe irAE. In the subset analysis focusing on severe cardiovascular and neurological irAEs, rechallenge with ICIs was generally well tolerated. However, one patient treated with anti-PD1 experienced a relapse of grade 2 aseptic meningitis. Overall, our findings suggest that rechallenging with ICIs after severe irAEs, including those affecting the cardiovascular and neurological systems, may be safe, particularly after irAE regression and corticosteroid withdrawal. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Practical management of patients on Janus kinase inhibitor (JAKi) therapy: Practical fact sheets drawn up by the Rheumatism and Inflammation Club (CRI), a group endorsed by the French Society for Rheumatology (SFR)

Author

Richez, Christophe, Morel, Jacques, Cornec, Divi, Daïen, Claire, Goupille, Philippe, Lazaro, Estibaliz, Lequerré, Thierry, Nocturne, Gaëtane, de Lédinghen, Victor, Le Goff, Benoit, Pourcher, Valérie, Prati, Clément, Seror, Raphaèle, Tournadre, Anne, Truchetet, Marie-Elise, Sibilia, Jean, and Pham, Thao

Published
2019
Full Text
View/download PDF

34. Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseases.

Author

Thomas, Marion, Masson, Maeva, Bitoun, Samuel, Hamroun, Sabrina, Seror, Raphaele, Dupuy, Henry, Lazaro, Estibaliz, Richez, Christophe, Allanore, Yannick, and Avouac, Jérôme

Subjects
THERAPEUTIC use of monoclonal antibodies, RISK assessment, COMBINATION drug therapy, IMMUNOSUPPRESSIVE agents, SCIENTIFIC observation, SEVERITY of illness index, DESCRIPTIVE statistics, COVID-19 vaccines, PRE-exposure prophylaxis, ANTIGENS, AUTOIMMUNE diseases, DRUG efficacy, RESEARCH, CONFIDENCE intervals, TREATMENT failure, COVID-19, DISEASE incidence, COMORBIDITY, EVALUATION
Abstract

Objective To describe the clinical efficacy of tixagevimab/cilgavimab in pre-exposure prophylaxis in patients at risk of severe coronavirus disease 2019 (COVID-19) and unresponsive to vaccination (anti-severe acute respiratory syndrome coronavirus 2 antibodies <260 binding antibody units/ml) in rheumatology. Methods In this multicentre observational study we included patients with autoimmune or inflammatory diseases who received pre-exposure prophylaxis with tixagevimab/cilgavimab between December 2021 and August 2022. The endpoint was incidence of COVID-19 and its severity. Results Tixagevimab/cilgavimab was administered to 115 patients with a median age of 62 years [interquartile range (IQR) 52–71], chronic arthritis (n  = 53), connective tissue disease (n  = 38) or vasculitis (n  = 11). The main background immunosuppressants were rituximab (n  = 98), corticosteroids [ n  = 62; median dose 5 mg (95% CI 5–8)] and methotrexate (n  = 48). During a median follow-up of 128 days (IQR 93–173), COVID-19 occurred in 23/115 patients (20%) and the omicron variant was identified for the eight genotyped patients. During the study period, the average weekly incidence was 1071/100 000 inhabitants in Île-de-France vs 588/100 000 in our patients. Patients who received a two-injection regimen had a lower risk of infection than those with a single injection [16/49 (33%) vs 5/64 (8%), P  = 0.0012]. The COVID-19-positive patients did not differ from uninfected patients concerning age, comorbidities, underlying rheumatic disease and immunosuppressants. All COVID-19 cases were non-severe. The tolerance of injections was excellent. Conclusion In a population with autoimmune or inflammatory diseases at risk of severe COVID-19 unresponsive to vaccination, pre-exposure prophylaxis withy tixagevimab/cilgavimab was associated with a lower incidence of COVID-19 and no severe infections. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial

Author

Allaguy-Salachy, Hélène, Arsandaux, Julie, Aubin, Henri-Jean, Bénard, Antoine, Bernard-Henry, Claudine, Beuscart, Aurélie, Beuscart, Claude, Borgne, Anne, Bouchaud, Olivier, Brahmy, Charles, Breilh, Dominique, Cabié, André, Cateland, Claude, Chêne, Geneviève, Cheret, Antoine, Couffin-Cadiergues, Sandrine, Dautzenberg, Marie-Dominique, Dellamonica, Pierre, Denis-Kandel, Pascale, Denis-Vatant, Christine, Detilleux, Michel, Dupon, Michel, Duval, Xavier, Duvivier, Claudine, El Harrar, Brigitte, Fagard, Catherine, Fagnen Sylvaire, Marie Christine, Ferret, Samuel, Guillermet, Simone, Jacomet, Christine, Jeantils, Vincent, Katlama, Christine, Korzek, Marek, Lazaro, Estibaliz, Le Maitre, Béatrice, Lucht, Frédéric, Maquet, Marianne, Mathieu, Audrey, May, Thierry, Mercié, Patrick, Merigeaud, Sonia, Moinot, Laetitia, Molina, Jean-Michel, Morlat, Philippe, Naqvi, Alissa, Neau, Didier, Perriot, Jean, Pierre-François, Sandrine, Poizot-Martin, Isabelle, Quoix, Elisabeth, Rebillard, Matthieu, Reynes, Jacques, Roussillon, Caroline, Rosenthal, Eric, Sainte-Marie, Thierry, Salmon-Céron, Dominique, Schneider, Luminita, Simon, Anne, Soussi, Malika, Sotto, Albert, Spadone, Christian, Spire, Bruno, Taburet, Anne-Marie, Teicher, Elina, Termote, Monique, Trosini-Desert, Valery, Verdon, Renaud, Viard, Jean-Paul, Vittecoq, Daniel, Vray, Muriel, Wirth, Nathalie, Youssi, David, and Zucman, David

Published
2018
Full Text
View/download PDF

43. Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry.

Author

de Valence, Benjamin, Delaune, Marion, Yann Nguyen, Jachiet, Vincent, Heiblig, Mael, Jean, Alexis, Tuczkiewicz, Stanislas Riescher, Henneton, Pierrick, Guilpain, Philippe, Schleinitz, Nicolas, Le Guenno, Guillaume, Lobbes, Hervé, Lacombe, Valentin, Ardois, Samuel, Lazaro, Estibaliz, Langlois, Vincent, Outh, Roderau, Vinit, Julien, Martellosio, Jean-Philippe, and Decker, Paul

Published
2024
Full Text
View/download PDF

44. Demographic and clinical characteristics of patients with coexistence of systemic sclerosis and atopy: A cross‐sectional study.

Author

Archimbaud, Julie, Barnetche, Thomas, Lazaro, Estibaliz, Constans, Joël, Duffau, Pierre, Truchetet, Marie‐Elise, and Seneschal, Julien

Subjects
ATOPY, SYSTEMIC scleroderma, DEMOGRAPHIC characteristics, CROSS-sectional method, VASCULAR remodeling, BRAIN natriuretic factor
Abstract

This article presents a study that investigated the relationship between atopic conditions and systemic sclerosis (SSc) in patients. The study found that SSc patients with atopic conditions were significantly associated with pulmonary arterial hypertension (PAH). Additionally, patients with atopy had fewer telangiectasias and a lower frequency of digital ulcers, which are indicators of PAH. However, the study had limitations, such as being conducted at a single center and relying on self-reported symptoms of atopy. More research is necessary to validate these findings in larger patient populations. [Extracted from the article]

Published
2024
Full Text
View/download PDF

45. Systematic Aetiological Assessment of Myocarditis: A Prospective Cohort Study.

Author

Michel, Vincent, Lazaro, Estibaliz, Fauthoux, Thomas, Cetran, Laura, Contin-Bordes, Cécile, Blanco, Patrick, Seguy, Benjamin, Baudinet, Thomas, Coste, Pierre, and Gerbaud, Edouard

Subjects
*STILL'S disease, *MYOCARDITIS, *ANTINUCLEAR factors, *LONGITUDINAL method, *COHORT analysis
Abstract

Background: Myocarditis is commonly diagnosed in the intensive care cardiology unit (ICCU). No current recommendation nor guideline aids exist for aetiological assessments. Methods: From September 2021 to October 2023, 84 patients with acute myocarditis underwent thorough and systematic serum and blood cell panel evaluations to determine the most common causes of myocarditis. Results: Of the 84 patients (median age 34 years, range 22–41 years, 79% male), 16 presented with complicated myocarditis. The systematic aetiological assessment revealed that 36% of patients were positive for lupus anticoagulant, 12% for antinuclear antibodies, 8% for anti-heart antibodies, and 12% for anti-striated muscle antibodies. Viral serology did not yield any significant results. After the aetiological assessment, one patient was diagnosed with an autoimmune inflammatory disorder (Still's disease). T-cell subset analyses indicated that myocarditis severity tended to increase with the T-cell lymphopenia status. Conclusions: A comprehensive, systematic aetiological assessment was of limited value in terms of predicting the clinical or therapeutic outcomes in myocarditis patients presenting to the ICCU. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

46. Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus.

Author

Gensous, Noémie, Lazaro, Estibaliz, Blanco, Patrick, and Richez, Christophe

Subjects
THERAPEUTICS, TYPE I interferons, SYSTEMIC lupus erythematosus, PATIENT experience, MONOCLONAL antibodies, PATIENTS' attitudes
Abstract

Type 1 interferons (IFNs) play a crucial role in the pathogenesis of systemic lupus erythematosus (SLE) and various type I IFNs targeting therapeutic approaches have been developed. Anifrolumab, a monoclonal antibody that binds to the subunit 1 of the type I IFN receptor, has acquired considerable interest and has entered different clinical human trials willing to evaluate its efficacy and safety. This review summarizes the data obtained in phases 1, 2, and 3 clinical trials of anifrolumab for SLE patients. A focus is made on data of clinical efficacy and safety obtained in MUSE, TULIP-1 and TULIP-2 trials. Anifrolumab is a promising therapeutic option for patients with SLE, currently authorized for moderate-to-severe SLE. Extensive real-world use is now going to generate data required to gain experience on the type of patients who benefit the most from the drug, and the exact positioning of anifrolumab in the therapeutic plan. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Disrupting the CD95–PLCγ1 interaction prevents Th17-driven inflammation

Author

Poissonnier, Amanda, Guégan, Jean-Philippe, Nguyen, Ha Thanh, Best, Daniel, Levoin, Nicolas, Kozlov, Guennadi, Gehring, Kalle, Pineau, Raphael, Jouan, Florence, Morere, Lucie, Martin, Sophie, Thomas, Mélissa, Lazaro, Estibaliz, Douchet, Isabelle, Ducret, Thomas, van de Weghe, Pierre, Blanco, Patrick, Jean, Mickael, Vacher, Pierre, and Legembre, Patrick

Published
2018
Full Text
View/download PDF

49. Benralizumab for eosinophilic granulomatosis with polyangiitis.

Author

Cottu, Adrien, Groh, Matthieu, Desaintjean, Charlene, Marchand-Adam, Sylvain, Guillevin, Loïc, Puechal, Xavier, Beaumesnil, Stacy, Lazaro, Estibaliz, Samson, Maxime, Taille, Camille, Durel, Cécile-Audrey, Diot, Elizabeth, Nicolas, Sarah, Guilleminault, Laurent, Ebbo, Mikael, Cathebras, Pascal, Dupin, Clairelyne, Yildiz, Halil, Belfeki, Nabil, and Pugnet, Grégory

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results